These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 28501118)

  • 1. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
    Mirkin KA; Hollenbeak CS; Wong J
    J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
    Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
    Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.
    Gratian L; Pura J; Dinan M; Roman S; Reed S; Sosa JA
    Ann Surg Oncol; 2014 Oct; 21(11):3515-21. PubMed ID: 24841347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level.
    Concors SJ; Sinnamon AJ; Ecker BL; Metz DC; Vollmer CM; Fraker DL; Roses RE
    HPB (Oxford); 2020 Jan; 22(1):83-90. PubMed ID: 31239188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
    Yao W; Wang W; Li G
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors.
    Raoof M; Jutric Z; Melstrom LG; Lee B; Li D; Warner SG; Fong Y; Singh G
    Surgery; 2019 Apr; 165(4):760-766. PubMed ID: 30447803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
    Kuo EJ; Salem RR
    Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.
    Wang SE; Su CH; Kuo YJ; Shyr YM; Li AF; Chen TH; Wu CW; Lee CH
    Pancreas; 2011 Mar; 40(2):253-9. PubMed ID: 20966805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
    Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.
    Sallinen VJ; Le Large TYS; Tieftrunk E; Galeev S; Kovalenko Z; Haugvik SP; Antila A; Franklin O; Martinez-Moneo E; Robinson SM; Panzuto F; Regenet N; Muffatti F; Partelli S; Wiese D; Ruszniewski P; Dousset B; Edwin B; Bartsch DK; Sauvanet A; Falconi M; Ceyhan GO; Gaujoux S;
    HPB (Oxford); 2018 Mar; 20(3):251-259. PubMed ID: 28988702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.